ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE